About
Small Molecules
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
3
As Collaborator
2
Total Enrollment
304
By Phase
PHASE2: 1PHASE1: 4
By Status
RECRUITING: 3ACTIVE_NOT_RECRUITING: 1UNKNOWN: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
Today
Hover over trial bars to see details
Recent Trials
NCT06978088Collaborator
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
PHASE2Recruiting
34 participants
Started: Jun 1, 2025 · Completed: Jun 1, 2034
NCT04771572Lead Sponsor
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
PHASE1Recruiting
100 participants
Started: Aug 23, 2021 · Completed: Oct 1, 2025
NCT04775745Lead Sponsor
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
PHASE1Recruiting
60 participants
Started: Jul 19, 2021 · Completed: Dec 31, 2025
NCT04139434Lead Sponsor
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
PHASE1Active, not recruiting
36 participants
Started: Jul 6, 2020 · Completed: Jan 31, 2025
NCT04356846Collaborator
A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma
PHASE1Unknown
74 participants
Started: May 1, 2020 · Completed: Dec 1, 2023
Locations (1)
Headquarters
Pleasanton, CA, United States
Map
Loading map...